PEAK6 Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q4
Sell
-13,400
Closed -$67K 5861
2015
Q3
$67K Sell
13,400
-40,400
-75% -$232K ﹤0.01% 4555
2015
Q2
$346K Buy
53,800
+27,500
+105% +$184K ﹤0.01% 3158
2015
Q1
$185K Sell
26,300
-12,800
-33% -$92.7K ﹤0.01% 3509
2014
Q4
$301K Sell
39,100
-1,900
-5% -$15K ﹤0.01% 3023
2014
Q3
$306K Buy
41,000
+22,200
+118% +$206K ﹤0.01% 2918
2014
Q2
$182K Sell
18,800
-15,300
-45% -$136K ﹤0.01% 3305
2014
Q1
$283K Sell
34,100
-45,700
-57% -$392K ﹤0.01% 3100
2013
Q4
$674K Buy
+79,800
New +$672K ﹤0.01% 2404
2013
Q3
Sell
-101,000
Closed -$780K 5952
2013
Q2
$780K Buy
+101,000
New +$788K ﹤0.01% 2363

Other funds holding PDLI

PEAK6 Group's PDLI Position: Q4 2016 in Review

PEAK6 Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 17,815 shares — an estimated $60K sold.

PEAK6 Group first reported a position in PDLI in Q4 2013 and held it in 8 quarters. The position peaked at $106K in Q2 2016. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • PEAK6 Group reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • PEAK6 Group sold 17,815 PDL BioPharma, Inc. shares in Q4 2016, an estimated $60K.
  • PEAK6 Group first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 8 quarters.
  • PEAK6 Group's PDL BioPharma, Inc. position peaked at $106K in Q2 2016.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on PEAK6 Group's 13F filing for Q4 2016, filed 13 Feb 2017.